› New Innovation opens window of opportunity for current users of the INTERCEPT™ Blood System for platelets.

New Innovation opens window of opportunity for current users of the INTERCEPT™ Blood System for platelets.

The Triple Storage processing set can open a new window of opportunity for your blood centre when you perform INTERCEPT-treatment on:

Apheresis platelets

Buffy coat platelets

Watch this video to find out more about the new innovative concept of pool-of-pools.

How the Triple Storage processing set can open a new window of opportunity when you perform INTERCEPT-treatment on apheresis platelets?

  • By allowing treatment of single donor platelets with platelet content >8x1011 with 1 INTERCEPT procedure.
  • By reinitiating apheresis collections with target platelet content >8x1011 and reducing as such the required number of apheresis procedures, apheresis disposables, apheresis donors and INTERCEPT procedures to generate  the same amount of pathogen-inactivated apheresis platelets.
  • By enabling earlier release of pathogen-inactivated platelets as fewer INTERCEPT procedures are required to produce the same amount of apheresis platelet doses and minimum CAD time is reduced by 2 hours.
  • By eliminating the potential contamination risk inherent with sterile docking of additional platelet storage bags as 3 platelet storage bags are integrated in the Triple Storage processing set.

How can the Triple Storage processing set open a new window of opportunity when you perform INTERCEPT-treatment on buffy coat platelets?

  • By enabling the treatment of 2 or 3 buffy coat-derived platelet units with 1 INTERCEPT procedure through the new innovative concept of pool-of-pools.
  • By enabling the pathogen inactivation of multiple buffy coat platelet doses at once, regardless of platelet dose requirement or buffy coat production method (manual or semi-automated).
  • By enabling the pathogen inactivation of 2 buffy coat-derived platelet units with 1 INTERCEPT procedure if platelet dose requirements are >2.5x1011.
  • By enabling the pathogen inactivation of 3 buffy coat-derived platelet units with 1 INTERCEPT procedure if platelet dose requirements are ≤2.5x1011.
  • By enabling savings on hands-on time and INTERCEPT disposables as 50 to 66% fewer INTERCEPT procedures are required to pathogen inactivate the same amount of buffy coat-derived platelet units.
  • By reducing the number of buffy coat procedures and disposables by 33% through the increase of buffy coat pool size from 4 to 6, and treatment of 2 buffy coat-derived platelet units with 1 INTERCEPT procedure.
  • By enabling earlier release of pathogen-inactivated platelets as fewer INTERCEPT procedures are required to produce the same amount of buffy coat-derived platelets and minimum CAD time is reduced by 2 hours.
  • By eliminating the potential contamination risk inherent with sterile docking of additional platelet storage bags as 3 platelet storage bags are integrated in the Triple Storage processing set.